NOT-DA-13-021: Notice of NIDA's Participation in RFA-AA-13-003 Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01)

Notice of NIDA's Participation in RFA-AA-13-003 Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01)

Notice Number: NOT-DA-13-021

Key Dates
Release Date: April 3, 2013

Related Announcements
RFA-AA-13-003

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to inform potential applicants of the National Institute on Drug Abuse (NIDA)'s participation, effective immediately, in the Funding Opportunity Announcement (FOA) RFA-AA-13-003 entitled "Research on Comparative Effectiveness and Implementation of HIV/AIDS and Alcohol Interventions (R01)."

The following sections of RFA-AA-13-003 have been updated to reflect the participation of NIDA in this FOA:

Part 1. Overview Information

Components of Participating Organizations
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.273, 93.279

Part 2. Section I. Funding Opportunity Description

For this FOA, NIDA's interest includes:

NIDA's principal interest is to understand how evidence-based interventions are transported into and maintain their potency in real-world community-based practice settings (e.g., ERs, primary care, criminal justice settings, substance abuse treatment etc.). Several promising integrated behavioral and biomedical approaches have shown positive outcomes in improving engagement and retention in HIV care, reducing substance abuse (abused substances, alcohol, and tobacco), and promoting greater adherence to HIV treatment and overall medical management. However, there remains a large gap in translation from research models into combination approaches that are effective in “real world” settings, such as front-line community based organizations, substance abuse treatment venues and other direct providers of clinical care. Maximizing adherence in the broadest sense is key to effective implementation. Specifically, NIDA encourages research to explore mechanisms to successfully transfer and sustain efficacious integrated combination interventions (e.g., targeting use of and adherence to HAART, screening and risk reduction, engagement and long-term maintenance in HIV care, and overall medical management for co-morbid conditions, such as substance use, mental health impairments, Hepatitis C, TB) for HIV+ populations in real-world practice settings.

Part 2. Section II. Award Information

Funds Available and Anticipated Number of Awards
NIDA intends to commit $3.5M in FY13 funds to support approximately 6 awards.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Lynda Erinoff, Ph.D.
AIDS Research Program
National Institute on Drug Abuse (NIDA)
Phone: 301-402-1972
Email: [email protected]

Financial/Grants Management Contact(s)
Carol Alderson
Grants Management Branch
National Institute on Drug Abuse (NIDA)
Phone: 301-933-6196
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Lynda Erinoff, Ph.D.
National Institute on Drug Abuse
6001 Executive Blvd
Rm 5274 MSC 9581
Bethesda, MD 20892
Telephone: 301-402-1972
Fax: 301-594-5610
Email: [email protected]